Share
    NEW SEARCH RETURN TO SEARCH RESULTS
Number: 201204004 Principal Investigator: Bartlett, Nancy
Title: A Phase 2 Randomized Open-label Study of MEDI-551 in Adults with Relapsed or Refractory DLBCL
Phase: II Disease Site: Non-Hodgkin's Lymphoma
Participating Site(s):
 
Main Campus
Map and Directions
West County
Map and Directions
 
Contact: 800-600-3606 or info@ccadmin.wustl.edu

Description:
The overall purpose of the study is to determine if MEDI-551, when used in combination with salvage chemotherapy, Ifosfamide-carboplatin-etoposide (ICE) or Dexamethasone-cytarabine (DHAP) in patients with relapsed or refractory DLBCL who are eligible for autologous stem cell transplant (ASCT), has superior efficacy compared to rituximab in the same population.
 
More Information:
ClinicalTrials.gov Link
Internal Protocol Documents (requires Siteman administrative database password)